0.7863USD-4.23%Mkt Cap: 8.35M USDP/E: —Last update: 2026-05-26
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap8.35M USD
Enterprise Value-9.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-16.23M USD
Revenue/Share—
Last Price0.7863 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS3724461047
Valuation
P/E (Trailing)—
P/E (Forward)-0.37
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.34
EPS (TTM)-5.06
EPS (Forward)-2.18
52W Range
0.74000% of range55.00
52W High55.00 USD
52W Low0.7400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-203.83%
ROA-159.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.31M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-108.06%
Net Debt-18.05M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.61
Quick Ratio5.38
Book Value/Sh2.419 USD
Cash/Share1.705 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateOct 21, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.10.59M
Float10.56M
Insiders0.97%
Institutions1.01%
Short Interest
Short Ratio1.0d
Short % Float10.79%
Short % Out.10.77%
Shares Short1.12M
Short (prev mo.)385.86K
Technical
SMA 501.294 (-39.2%)
SMA 2004.889 (-83.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)932.40K
Avg Vol (10d)231.57K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—